Clinical Trial: An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naive Participants With Primary Immunodeficiency (PID)

U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07076446) titled 'An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naive Participants With Primary Immunodeficiency (PID)' on July 15.

Brief Summary: This is an open-label, multicenter, phase 4 study in IG treatment-naive participants with PID, conducted in the United States (US), to assess the PK, safety, and tolerability of IgPro20. The primary objective of this study is to characterize the PK of IgPro20 and to assess the safety and tolerability of IgPro20 in IG treatment-naive participants with PID who are aged greater than or equal to (>=) 18 ye...